NPS Pharmaceuticals, Inc.  

(Public, NASDAQ:NPSP)   Watch this stock  
Find more results for NPSP
0.0000
Real-time:  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 4.99B
P/E     -
Div/yield     -
EPS -0.08
Shares 108.58M
Beta     -
Inst. own 101%

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -2.96% -3.89%
Operating margin 1.28% 2.25%
EBITD margin - 3.74%
Return on average assets -2.77% -2.99%
Return on average equity -5.98% -7.29%
Employees 365 -
CDP Score - -

Address

550 Hills Dr
BEDMINSTER, NJ 07921-1537
United States - Map
+1-908-4505300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.